Skip to main content

Table 1 Baseline characteristics according to maximum standardized uptake values a

From: Standardized uptake value of 18F-fluorodeoxyglucose positron emission tomography for prediction of tumor recurrence in breast cancer beyond tumor burden

Characteristics All patients High SUV Low SUV P -value b
Age at diagnosis, yr     0.698
  Median (range) 48 (25 to 80) 48 (25 to 79) 49 (28 to 80)
Histology     <0.001
  Invasive ductal carcinoma 416 (83.9) 173 (87.8) 243 (81.3)  
  Invasive lobular carcinoma 22 (4.4) 1 (0.5) 21 (7.0)  
  Mucinous carcinoma 13 (2.6) 2 (1.0) 11 (3.7)  
  Tubular carcinoma 6 (1.2) 0 (0.0) 6 (2.0)  
  Medullary carcinoma 4 (0.8) 4 (0.8) 0 (0.0)  
  Other invasive carcinoma 35 (7.7) 17 (8.6) 18 (6.0)  
T classification     <0.001
  T1 270 (54.4) 68 (34.5) 202 (67.6)  
  T2 217 (43.8) 126 (64.0) 91 (30.4)  
  T3 9 (1.8) 3 (1.5) 6 (2.0)  
N classification     0.016
  N0 329 (66.3) 115 (58.4) 214 (71.6)  
  N1 123 (24.8) 59 (29.9) 64 (21.4)  
  N2 30 (6.0) 17 (8.6) 13 (4.3)  
  N3 14 (2.8) 6 (3.0) 8 (2.7)  
AJCC stage     <0.001
  I 200 (40.3) 42 (21.3) 158 (52.8)  
  II 252 (50.8) 131 (66.5) 121 (40.5)  
  III 44 (8.9) 24 (12.2) 20 (6.7)  
Histologic grade c     <0.001
  1 157 (35.0) 43 (22.8) 114 (44.0)  
  2 199 (44.4) 78 (41.3) 121 (46.7)  
  3 92 (20.5) 68 (36.0) 24 (9.3)  
ER     0.001
  Positive 304 (61.3) 102 (51.8) 202 (67.6)  
  Negative 192 (38.7) 95 (48.2) 97 (32.4)  
PR     0.005
  Positive 293 (59.1) 97 (49.2) 196 (65.6)  
  Negative 203 (40.9) 100 (50.8) 103 (34.4)  
HER-2 d     <0.001
  Positive 127 (25.6) 72 (36.5) 55 (18.4)  
  Negative 369 (74.4) 125 (63.5) 244 (81.6)  
Ki67     <0.001
  High 102 (20.6) 64 (32.5) 38 (12.7)  
  Low 394 (79.4) 133(67.5) 261 (87.3)  
Subtypes     <0.001
  Luminal A 257 (51.8) 71 (36.0) 186 (62.2)  
  Luminal B 71 (14.4) 39 (19.8) 32 (10.7)  
  HER2 83 (16.7) 45 (22.8) 38 (12.7)  
  Triple negative 85 (17.1) 42 (21.3) 43 (14.4)  
Surgery type     0.043
  Mastectomy 352 (70.9) 150 (76.1) 202 (67.5)  
  Breast-conserving surgery 144 (29.1) 47 (24.9) 97 (32.5)  
Adjuvant chemotherapy     <0.001
  Yes 347 (70.0) 162 (82.2) 185 (61.9)  
  No 149 (30.0) 35 (17.8) 114 (38.1)  
Adjuvant endocrine therapy     0.001
  Yes 332 (66.9) 114 (57.9) 218 (72.9)  
  No 164 (33.1) 83 (42.1) 81 (27.1)  
Adjuvant radiotherapy     0.915
  Yes 189 (38.1) 74 (37.6) 115 (38.5)  
  No 307 (61.9) 123 (62.4) 184 (61.5)  
  1. aAJCC, American Joint Committee on Cancer; ER, Estrogen receptor; HER2, Human epidermal growth factor receptor 2; PR, Progesterone receptor; SUVmax, Maximum standardized uptake value. Data are number of patients (%), except for age. bχ2 test. cData with missing values. dHER2 positivity was defined as a 3+ score on immunohistochemistry or amplification on fluorescence in situ hybridization.